参考文献
[1] 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2022概要 [J]. 中国循环杂志, 2023,38 (6): 583‑612. DOI: 10.3969/j.issn.1000‑3614.2023.06.001.
[2] 中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年) [J]. 中华心血管病杂志, 2023,51 (3): 221‑255. DOI: 10.3760/cma.j.cn112148‑20230119‑00038.
[3] Zhang M, Deng Q, Wang L, et al. Prevalence of dyslipidemia and achievement of low‑density lipoprotein cholesterol targets in Chinese adults: A nationally representative survey of 163,641 adults [J]. Int J Cardiol,2018,260: 196‑203. DOI: 10.1016/j.ijcard.2017.12.069.
[4] Rikhi R, Shapiro MD. Newer and emerging LDL‑C lowering agents and implications for ASCVD residual risk [J]. J Clin Med,2022,11 (15): 4611. DOI: 10.3390/jcm11154611.
[5] Zhao B, He X, Wu J, et al. Adherence to statins and its impact on clinical outcomes: a retrospective population‑based study in China[J]. BMC Cardiovasc Disord, 2020,20(1):282. DOI: 10.1186/s12872‑020‑01566‑2.
[6] Shau WY, Lai CL, Huang ST, et al. Statin adherence and persistence on secondary prevention of cardiovascular disease in Taiwan[J]. Heart Asia, 2019,11(2):e011176. DOI: 10.1136/heartasia‑2018‑011176.
[7] Rymer JA, Mues KE, Monda KL, et al. Use of low‑density lipoprotein‑lowering therapies before and after PCSK9 inhibitor initiation[J]. J Am Heart Assoc, 2020,9(9):e014347. DOI: 10.1161/JAHA.119.014347.
[8] Liu YQ, Li DD, Chai M, et al. Real world effectiveness of PCSK‑9 inhibitors combined with statins versus statins‑based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China (RWE‑PCSK study)[J]. J Geriatr Cardiol, 2021,18(4):261‑270. DOI: 10.11909/j.issn.1671‑5411.2021.04.005.
[9] Niu C, Parlapalli A, Neenan J, et al. Abstract 12945: six‑month adherence among early inclisiran initiators vs. anti‑PCSK9 mAbs users: A retrospective analysis of US claims databases [C]. Philadelphia:AHA Scientific Sessions,2023.
[10] Ference BA, Graham I, Tokgozoglu L, et al. Impact of lipids on cardiovascular health: JACC health promotion series [J]. J Am Coll Cardiol,2018,72 (10): 1141‑1156. DOI: 10.1016/j.jacc.2018.06.046.
[11] Bangalore S, Breazna A, DeMicco DA, et al. Visit‑to‑visit low‑density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial[J]. J Am Coll Cardiol, 2015,65(15):1539‑1548. DOI: 10.1016/j.jacc.2015.02.017.
[12] Nayor M, Murthy VL, Shah RV. For non‑HDL cholesterol, "lower is better" but "lower for longer" may be best[J]. Circ Res, 2020,126(7):836‑838. DOI: 10.1161/CIRCRESAHA.120.316697.
[13] Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia[J]. N Engl J Med, 2020,382(16):1520‑1530. DOI: 10.1056/NEJMoa1913805.
[14] Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol[J]. N Engl J Med, 2020,382(16):1507‑1519. DOI: 10.1056/NEJMoa1912387.
[15] 霍勇, 李勇, 韩雅君, 等. 英克司兰钠注射液在中国大陆ASCVD或ASCVD高危受试者中的有效性和安全性:ORION‑18研究亚组分析 [C]. 北京:第34届长城心脏病学大会,2023.
[16] Scicchitano P, Milo M, Mallamaci R, et al. Inclisiran in lipid management: A literature overview and future perspectives[J]. Biomed Pharmacother, 2021,143:112227. DOI: 10.1016/j.biopha.2021.112227.
[17] Traber GM, Yu AM. RNAi‑based therapeutics and novel RNA bioengineering technologies[J]. J Pharmacol Exp Ther, 2023,384(1):133‑154. DOI: 10.1124/jpet.122.001234.
[18] Lee HS, Seok H, Lee DH, et al. Abasic pivot substitution harnesses target specificity of RNA interference[J]. Nat Commun, 2015,6:10154. DOI: 10.1038/ncomms10154.
[19] Khvorova A. Oligonucleotide therapeutics ‑a new class of cholesterol‑lowering drugs[J]. N Engl J Med, 2017,376(1):4‑7. DOI: 10.1056/NEJMp1614154.
[20] Tromp TR, Stroes E, Hovingh GK. Gene‑based therapy in lipid management: the winding road from promise to practice[J]. Expert Opin Investig Drugs, 2020,29(5):483‑493. DOI: 10.1080/13543784.2020.1757070.
[21] Lancellotti P, Oury C. A highly durable rnai therapeutic inhibitor of PCSK9[J]. N Engl J Med, 2017,376(18):e38. DOI: 10.1056/NEJMc1703361.
[22] Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol[J]. N Engl J Med, 2017,376(15):1430‑1440. DOI: 10.1056/NEJMoa1615758.
[23] Ray KK, Stoekenbroek RM, Kallend D, et al. Effect of 1 or 2 doses of inclisiran on low‑density lipoprotein cholesterol levels: one‑year follow‑up of the ORION‑1 randomized clinical trial[J]. JAMA Cardiol, 2019,4(11):1067‑1075. DOI: 10.1001/jamacardio.2019.3502.
[24] Gosselin NH, Schuck V, Barriere O, et al. Translational population‑pharmacodynamic modeling of a novel long‑acting siRNA therapy, inclisiran, for the treatment of hypercholesterolemia[J]. Clin Pharmacol Ther, 2023,113(2):328‑338. DOI: 10.1002/cpt.2774.
[25] Luo Z, Huang Z, Sun F, et al. The clinical effects of inclisiran, a first‑in‑class LDL‑C lowering siRNA therapy, on the LDL‑C levels in Chinese patients with hypercholesterolemia[J]. J Clin Lipidol, 2023,17(3):392‑400. DOI: 10.1016/j.jacl.2023.04.010.
[26] Huo Y, Lesogor A, Lee CW, et al. Efficacy and safety of inclisiran in Asian patients: results from ORION‑18[J]. JACC Asia, 2024,4(2):123‑134. DOI: 10.1016/j.jacasi.2023.09.006.
[27] Rosenson RS, Hegele RA, Fazio S, et al. The evolving future of PCSK9 inhibitors[J]. J Am Coll Cardiol, 2018,72(3):314‑329. DOI: 10.1016/j.jacc.2018.04.054.
[28] Guedeney P, Sorrentino S, Giustino G, et al. Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta‑analysis[J]. Eur Heart J Cardiovasc Pharmacother, 2021,7(3):225‑235. DOI: 10.1093/ehjcvp/pvaa024.
[29] Roth EM, Goldberg AC, Catapano AL, et al. Antidrug antibodies in patients treated with alirocumab[J]. N Engl J Med, 2017,376(16):1589‑1590. DOI: 10.1056/NEJMc1616623.
[30] Wright RS, Ray KK, Raal FJ, et al. Pooled patient‑level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis[J]. J Am Coll Cardiol, 2021,77(9):1182‑1193. DOI: 10.1016/j.jacc.2020.12.058.
[31] Wright RS, Koenig W, Landmesser U, et al. Safety and tolerability of inclisiran for treatment of hypercholesterolemia in 7 clinical trials[J]. J Am Coll Cardiol, 2023,82(24):2251‑2261. DOI: 10.1016/j.jacc.2023.10.007.
[32] Zafrir B, Egbaria A, Stein N, et al. PCSK9 inhibition in clinical practice: Treatment patterns and attainment of lipid goals in a large health maintenance organization[J]. J Clin Lipidol, 2021,15(1):202‑211.e2. DOI: 10.1016/j.jacl.2020.11.004.
[33] Leqvio (Inclisiran Sodium). FDA Label [DB/OL]. (2021‑12‑22) [2023 ‑09‑10]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214012lbl.pdf.
[34] Leqvio (Inclisiran Sodium). FDA Label [DB/OL]. (2023‑07‑07) [2023 ‑09‑10]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214012s009lbl.pdf.
[35] Leqvio: EPAR‑Product information [DB/OL]. (2022‑08‑19) [2023 ‑09‑10]. https://www.ema.europa.eu/en/documents/product‑information/leqvio‑epar‑product‑information_en.pdf.
[36] Study to assess the real world effectiveness of inclisiran in Chinese adult patients with primary hypercholesterolemia or mixed dyslipidemia [DB/OL]. (2023‑06‑15) [2023 ‑10‑10]. https://classic.clinicaltrials.gov/ct2/show/NCT05118230.
[37] Huo Y, Fang P, Lou H. Real‑world early effectiveness and safety of inclisiran in China Pilot Zone: An interim analysis of 3‑month data from a prospective non‑interventional cohort study [C]. ESC Preventive Cardiology,2023.
[38] Efficacy and safety of inclisiran as monotherapy in Chinese adults with low or moderate ASCVD risk and elevated low‑density lipoprotein cholesterol. (V‑Mono China) [DB/OL]. (2023‑10‑10) [2023 ‑10‑26]. https://classic.clinicaltrials.gov/ct2/show/NCT05888103.
[39] Landmesser U, Koenig W, Leiter LA, et al. Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION‑10 and ORION‑11 Phase 3 randomised trials[J]. Atherosclerosis, 2023,386:117354. DOI: 10.1016/j.atherosclerosis.2023.117354.
[40] Koenig W, Ray KK, Kallend DG, et al. Efficacy and safety of inclisiran in patients with established cerebrovascular disease: pooled, post hoc analysis of the ORION‑9, ORION‑10 and ORION‑11, phase 3 randomised clinical trials[J/OL]. (2021‑10‑14) [2023‑09‑10]. https://academic.oup.com/eurheartj/article/42/Supplement_1/ehab724.2026/6391669?login=false.
[41] Koenig W, Ray KK, Landmesser U, et al. Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION‑9, ORION‑10, and ORION‑11[J]. Am J Prev Cardiol, 2023,14:100503. DOI: 10.1016/j.ajpc.2023.100503.
[42] Koenig W, Conde LG, Landmesser U, et al. Efficacy and safety of inclisiran in patients with polyvascular disease: Pooled, post hoc analysis of the ORION‑9, ORION‑10, and ORION‑11 phase 3 randomized controlled trials[J]. Cardiovasc Drugs Ther, 2022[Online ahead of print].DOI: 10.1007/s10557‑022‑07413‑0.
[43] Lawrence AL, David GK, Wolfgang K, et al. Abstract 11033: Efficacy and safety of inclisiran by baseline glycemic status: A post hoc pooled analysis of the ORION‑10 and ORION‑11 Phase III randomized controlled trials[J/OL]. (2021‑11‑08)[2023‑09‑10]..https://www.ahajournals.org/doi/10.1161/circ.144.suppl_1.11033.
[44] Landmesser U, Ray KK, Raal F, et al. Efficacy and safety of inclisiran in patients with chronic kidney disease ‑a pooled analysis from three phase 3 clinical trials (ORION‑9, -10 AND ‑11) [J]. J Am Coll Cardiol, 2021,77 (18_Supplement_1): 1458‑1458. DOI:10.1016/S0735‑1097(21)02816‑3.
[45] Krychtiuk KA, Ahrens I, Drexel H, et al. Acute LDL‑C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy[J]. Eur Heart J Acute Cardiovasc Care, 2022,11(12):939‑949. DOI: 10.1093/ehjacc/zuac123.
[46] A randomized trial assessing the effects of inclisiran on clinical outcomes among people with cardiovascular disease (ORION‑4) [DB/OL]. (2023‑11‑02) [2023 ‑11‑10]. https://classic.clinicaltrials.gov/ct2/show/NCT03705234.
[47] Study of inclisiran to prevent cardiovascular (CV) events in participants with established cardiovascular disease (VICTORION‑2P) [DB/OL]. (2023‑10‑27) [2023 ‑11‑10]. https://classic.clinicaltrials.gov/ct2/show/NCT05030428.
[48] A study of inclisiran to prevent cardiovascular events in high‑risk primary prevention patients [DB/OL]. (2023‑11‑03) [2023 ‑11‑10]. https://classic.clinicaltrials.gov/ct2/show/NCT05739383.
[49] Ray KK, Troquay R, Visseren F, et al. Long‑term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION‑3): results from the 4‑year open‑label extension of the ORION‑1 trial[J]. Lancet Diabetes Endocrinol, 2023,11(2):109‑119. DOI: 10.1016/S2213‑8587(22)00353‑9.
[50] Kallend D, Mason J, Smith PF, et al. An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: A phase I, randomized study[J]. Clin Transl Sci, 2022,15(11):2663‑2672. DOI: 10.1111/cts.13391.
[51] Maguregui A, Abe H. Developments in siRNA modification and ligand conjugated delivery to enhance RNA interference ability[J]. Chembiochem, 2020,21(13):1808‑1815. DOI: 10.1002/cbic.202000009.
[52] Leqvio: EPAR ‑Public assessment report [DB/OL]. (2021‑01‑06) [2023 ‑09‑10]. https://www.ema.europa.eu/en/documents/assessment‑report/leqvio‑epar‑public‑assessment‑report_en.pdf.
[53] Drug approval package: LEQVIO clinical review(s) [DB/OL]. (2022‑01‑20) [2023 ‑09‑10]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214012Orig1s000MedR.pdf.
[54] Wright RS, Collins MG, Stoekenbroek RM, et al. Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: An analysis of the ORION‑7 and ORION‑1 studies[J]. Mayo Clin Proc, 2020,95(1):77‑89. DOI: 10.1016/j.mayocp.2019.08.021.
[55] Atkinson AJ Jr, Umans JG. Pharmacokinetic studies in hemodialysis patients[J]. Clin Pharmacol Ther, 2009,86(5):548‑552. DOI: 10.1038/clpt.2009.147.
[56] Kallend D, Stoekenbroek R, He Y, et al. Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment[J]. J Clin Lipidol, 2022,16(2):208‑219. DOI: 10.1016/j.jacl.2022.01.001.
[57] R Scott S Wright, Ray KK, Raal FJ. Abstract 16427: efficacy and safety of Inclisiran according to age: a pooled analysis of phase III studies (ORION 9, 10 and 11)[J/OL]. (2020‑11‑12)[2023‑09‑10]. https://www.ahajournals.org/doi/10.1161/circ.142.suppl_3.16427.